Head-up tilt guided therapy significantly reduced the recurrence of symptoms compared to empiric therapy (6% vs 36%) or no therapy (67%) over a mean follow-up of 2.8 years (P<0.01).
Cohort (n=303)
Does head-up tilt guided therapy reduce the recurrence of symptoms compared to empiric or no therapy in patients with unexplained syncope and positive head-up tilt testing?
In patients with neurocardiogenic syncope, tailoring medical therapy based on repeated head-up tilt testing significantly reduces symptom recurrence compared to empiric treatment or no therapy.
Absolute Event Rate: 6% vs 36%
p-value: p=<0.01
OBJECTIVES: The purpose of this study was to evaluate the efficacy of different therapeutic approaches for patients with a history of syncope and positive head-up tilt testing. BACKGROUND: Head-up tilt testing has gained broad acceptance as a reliable diagnostic method for the assessment of patients with recurrent unexplained syncope. However, once the diagnosis is established, there is no consensus on the most appropriate treatment. In this respect, efficacy of drug therapy in preventing recurrence of symptoms in such patients is not entirely clear, and controversies exist regarding the need to confirm the effects of pharmacological interventions. METHODS: Clinical follow-up was obtained in 303 patients with a history of syncope and positive head-up tilt testing. After the diagnostic head-up tilt, patients were assigned to different therapeutic approaches according to their preference or logistic impediments. Of 303 patients, 44 received empiric therapy, 210 were treated with medications proven effective during repeated head-up tilt testing, and 49 refused or discontinued medical therapy. The three groups were similar with regard to age, sex, and clinical presentation. The mean follow-up was 2.8 +/- 1.8 years. Among the patients treated according to head-up tilt guided therapy, 130 were on beta blockers, 35 on theophylline, 10 on ephedrine, 31 on disopyramide, and 4 on miscellaneous regimens. Empiric treatment consisted of beta blockers in 37 of 44 patients and other drugs in the remaining patients. RESULTS: During the follow-up, recurrence of symptoms was experienced in 12 (6%) of the 210 patients receiving the head-up tilt guided therapy, 16 (36%) of 44 in the empiric therapy group, and 33 (67%) of 49 in the no therapy group. Recurrence of symptoms in patients on empiric or no therapy was significantly more frequent as compared to the head-up tilt guided therapy group (P < 0.01). CONCLUSIONS: In patients with unexplained syncope and positive upright tilt testing, therapeutic strategies identified on the basis of response during head-up tilt have a more positive impact on the recurrence of symptoms during follow-up.
Natale et al. (Sat,) conducted a cohort in Neurocardiogenic syncope (n=303). Head-up tilt guided therapy vs. Empiric therapy or no therapy was evaluated on Recurrence of symptoms (p=<0.01). Head-up tilt guided therapy significantly reduced the recurrence of symptoms compared to empiric therapy (6% vs 36%) or no therapy (67%) over a mean follow-up of 2.8 years (P<0.01).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: